F2 Isoprostanes levels in Metabolic Syndrome

Abstract

Metabolic disorder is portrayed by a group of cardiovascular (CV) causing factors including raised triglycerides, lessened HDL cholesterol, central obesity, hypertension, expanded fasting glucose and hyper insulinemia. MDA is the steady final result of lipid peroxidation. F2 Isoprostanes has been implicates the role for OS in pathophysiology of diseases. Our aim is to evaluate the Oxidative stress in Metabolic syndrome by measuring F2 Isoprostanes, MDA levels. The study was conducted at SLIMS, Puducherry. The study included 200 MetS patients and 200 Controls. In comparison to controls, MDA was significantly higher in MetS (p<0.001). In MetS group, there was a significant increase in F2 Isoprostanes compared to controls (p<0.001). Increased MDA, F2 Isoprostanes levels could be taken as an early marker of pathogenesis of MetS. The findings of the present study show that the individual components of MetS especially hyperglycemia, hyper triglyceridemia and obesity systolic blood pressure, diastolic blood pressure and BMR are related to OS. Markers of oxidative damage MDA and F2-isoprostanes and their relationship with self-reported chronic disease and metabolic syndrome as health indicators in a large adult sample. Present study’s results confirm that plasma F2-isoprostanes are likewise associated with the vast majority of the settled hazard factors for the improvement of atherosclerosis, including systolic pulse, triglycerides, waist circumference, and LDL-cholesterol levels, free of socio statistic and way of life factors.